350 results
CORRESP
WINT
Windtree Therapeutics Inc
1 Oct 10
Correspondence with SEC
12:00am
information.
The costs incurred by you during each period presented and to date on the project;
The nature, timing and estimated costs to be incurred by you … estimate of the nature, timing and costs necessary to complete these projects.
Securities and Exchange Commission
October 1, 2010
Page 3
Response
S-4
EX-5.2
WINT
Windtree Therapeutics Inc
26 Aug 97
Registration of securities issued in business combination transactions
12:00am
or data of a
financial, accounting or statistical nature, (ii) projections, estimates or any
other analyses dependent on future events described therein
8-K
EX-10.1
WINT
Windtree Therapeutics Inc
18 Jul 11
Departure of Directors or Certain Officers
12:00am
or relating to the Company on Executive’s behalf, any complaints, charges, claims, actions or other proceedings of any nature or description in or before any … nature or description in or before any court, administrative agency or other forum. To the extent permitted by law, the Company hereby agrees
8-K
EX-10.1
sdudqd5vj
3 Jan 06
Represents strategic decision to control manufacturing of Surfaxinâ and SRT pipeline
12:00am
8-K
EX-10.2
x949305sdo3kvxh
4 Sep 09
Discovery Labs Announces Date of 2009 Annual Shareholder Meeting
12:00am
8-K
EX-99.1
odk10up1 1wo
2 Jul 09
Discovery Labs Reports on Surfaxin End of Review Meeting with FDA
12:00am
8-K
1j7z ps0i
14 Feb 05
Other Events
12:00am
8-K/A
EX-10.1
o0esr1xizx59j zhtn5
11 May 12
Departure of Directors or Certain Officers
12:00am
8-K
EX-10.2
fyjm0lm5kli7bkum
2 Apr 13
Entry into a Material Definitive Agreement
12:00am
8-K
EX-10.2
1rp7d3fn4oql4a4
26 Oct 06
Entry into a Material Definitive Agreement
12:00am
8-K
EX-10.1
p29f 88maqlpn
2 Apr 13
Entry into a Material Definitive Agreement
12:00am